Despite announcing the completion of its first biologics site acquisition in the US, Syngene, the contract research arm of ...

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing ...

Johor is set to become Asia's largest insulin hub as India's leading biotechnology firm, Biocon Ltd, invests another RM1.1 ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from ...

(Reuters) -India’s Syngene International on Monday said it has acquired its first biologics facility in the United States ...

Syngene International acquires its first US manufacturing facility for USD 50 million, expanding its reach in human and animal health markets.

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...

Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.